Skip to main content
Sign In
 

Robert Lee Page, II, Pharm.D., MSPH, FCCP, FASHP, FASCP, FAHA, BCPS, CGP

Associated Faculty


Associate Professor

Departments of Clinical Pharmacy & Physical Medicine and Rehabilitation

(303) 724-2626

robert.page@ucdenver.edu

Professional Qualifications

Education

University of Colorado Denver School of Public Health, Aurora, CO, Doctor of Philosophy Health Systems Research, 2009-Present

University of Colorado Denver School of Medicine, Aurora, CO, MS in Public Health, 2009

University of Colorado Denver School of Medicine, Aurora, CO, Certificate in Public Health, 2007

MUSC Hospitals and Clinics College of Pharmacy, Charleston, SC, Pharmacotherapy Residency, 1998

Medical University of South Carolina College of Pharmacy, Charleston, SC, Doctor of Pharmacy, 1996

Medical University of South Carolina College of Pharmacy, Charleston, SC, BS in Pharmacy, 1994

Furman University Greenville, SC, Bs in Biology and Chemistry, 1991

Licensure Information/Registration Number

Colorado #15337
South Carolina #8554

Certifications

Board Certification in Pharmacotherapy (BCPS), December 2000-December 2007
BCPS, Recertified, January 2008-December 2014
BCPS, Added Qualifications in Cardiology, March 2005-March 2012
Certification in Geriatric Pharmacy (CGP), December 2005-December 2010

Curriculum Vitae

 Research and Scholarship Interests

Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina and Diabetes: Impact on Cardiac Interventions, Healthcare Resource Utilization and Expenditures. Gilead. Co-investigator (role: assisted with concept and protocol development). 10% salary offset, 5% effort. $158,754. July 2013-July 2014. On-going.

Estimating the Burden of Illness for Employees and Their Dependents with Acute Coronary Syndrome and Diabetes (role: assisted with protocol development, sub-study development, abstract preparation and presentation, manuscript preparation. Janssen.

Sedative Hypnotic Use by the Mentally Ill: A Medicaid Prescription Policy. National Institutes of Health (5R01-MH086310). Co-investigator (role: assisted with sub-study development and manuscript preparation). 20% salary offset, 10% effort. $273,804. June 2012-May 2013. Completed.

Pharmacogenomics of Calcineurin Nephrotoxicity in Cardiac Transplantation. American Heart Association- PMA Fall 09, Pacific Mountain Affiliate. Co-investigator (assisted with protocol development, patient enrollment, data collection and analysis)

Colorado Drug Utilization Review Program. Colorado Department of Health Policy and Financing. Principal Investigator-Clinical Lead (role: assist with development of retro-DUR, prospective DUR, clinical module development).

Clinical Pharmacology Of Aliskiren In Combination With Cyclosporine In Cardiac Transplantation. Co-investigator (role: assisted with protocol development, patient enrollment, data collection and analysis).

The Pharmacogenetics of Inhibitory Drug-Drug Interactions in Cardiac Transplantation. American Heart Association, Pacific Mountain Affiliate. Co-investigator (role: assisted with protocol development and data collection and analysis).

Physical Therapists Knowledge, Practice and Attitudes towards Oral Non-steroidal Anti-inflammatory Drugs (NSAIDs), Analgesics, and Nutritional Supplements/ Herbal Medicine. American Physical Therapy Association-Colorado Chapter. Co-investigator (role: assisted with protocol development, data analysis, data collection, and manuscript/abstract preparation).

The Relationship Between Melatonin and Tumor Necrosis Factor-alpha in Older Adults with Involuntary Weight Loss. American Association of Colleges of Pharmacy New Investigators Grant. Principal Investigator (role: conceived idea, wrote and submitted protocol, conducted data collection and data analysis.).

Optimization of Pharmacotherapy in Medically Acute Elderly Patients –the OPTIMAL Study. University of Colorado Hospital. Principal Investigator (role: conceived idea, wrote and submitted protocol, conducted all data collection and data analysis). $21,000. Principal Investigator. Funded.

Aquilante C (PI), Page RL2, Christian U, Brieke A. The pharmacogenetics of inhibitory drug-drug interactions in cardiac transplantation. American Heart Association, Pacific Mountain Affiliate. January 2007- December 2008. ($120,000). Role: Co-investigator, 10% effort; assisted with protocol development and data collection and analysis.

1

 Publications (within the last five years)

Peer Reviewed Publications

Jackevicuius CA, Page RL2, Chow S, et al. High-impact articles related to management of heart failure: 2008 update. Pharmacotherapy. 2009 Jan;29(1):82-120.

Page RL2, Hume AL, Trujillo JM, et al. Interprofessional education: principles and application. A framework for clinical pharmacy. Pharmacotherapy. 2009;29(7):880-881. Also available at http://www.pharmacotherapy.org/pdf/free/Pharm2903e_ACCP-Page-IPE-WP.pdf

Bainbridge JL, Page RL2, Ruscin MJ. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors. Neurol Clin. 2008;26:S85-96.

Page RL2, Cantu M, Lindenfeld J, Hergott L, Lowes B. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. Journal of Cardiovascular Medicine (Italian Heart Journal). 2008;9(9):922-925.

Page RL2, Nair K, Barton P. Effect of cost-sharing for prescription medications on health outcomes in older adults: a critical review of the literature and potential implications for managed care. Consultant Pharmacist. 2008;23:37-54.

Owens P, Garner J, Hergott L, Page RL2. Clopidogrel desensitization: patient case and review of published protocols. Pharmacotherapy. 2008; 28: 259-270.

Page RL2, Ruscin JM, Bainbridge JL, Brieke AA. Restless legs syndrome induced by escitalopram: case discussion and literature review. Pharmacotherapy. 2008;28:271-280.

Page RL2, Ferguson D, Cantu M. An alternative salvage regimen for Helicobacter Pylori resistant patients with heart failure. Cardiology. 2008;110:112-115.

Page RL2, Utz K, Wolfel G. Should ß-blockers be used in the treatment of cocaine associated acute coronary syndrome? Ann Pharmacother. 2007;41:2008-2013.

Turner CJ, Ellis S, Giles J, Maffeo C, Hansen L, Saseen JJ, Ulrich H, Valdez C, Altiere R, Bainbridge J, Page RL2, et al. A strategy to develop advanced pharmacy practice experiences. Am J Pharm Educ. 2007;71(3):46-49.

Page RL2, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis-case discussion and literature review. Pharmacotherapy. 2007;27(2):290-298.

Books and Book Chapters

Page RL2. Chapter 8. Heart transplantation. In: Crouch MA, ed. Cardiovascular Pharmacotherapy: A Point-of-care Guide, 1st ed. Bethesda, MD: American Society of Health Systems Pharmacists; 2009 (in production).

Page RL2, Nappi JM. Drug-induced hypotension. In: Tisdale J, ed. Drug-Induced Diseases: Prevention, Detection and Management, 2nd ed. Bethesda, MD: American Society of Health Systems Pharmacists; 2009 (in production).

Kim MS, Page RL2, Casserly I. Synthetic factor Xa inhibition in acute coronary syndromes. In: Askari, AT, Lincoff, AM, ed. Antithrombotic Drug Therapy in Cardiovascular Disease. 1st ed. New York: Springer Humana Press; 2008 (in press).

Page RL2, Nappi JM. Chapter 18. Myocardial infarction. In: Koda-Kimble MA, Young LY, eds. Applied Therapeutics: The Clinical Use of Drugs. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.

Nappi JM. Page RL2. Chapter 18. Diastolic heart failure and the cardiomyopathies. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiological Approach, 7th ed. New York, NY: McGraw-Hill; 2008.

Page RL2, Murphy JE. Chapter 15: Procainamide. In: Murphy JE, ed. Clinical Pharmacokinetics, 4th ed. Bethesda, MD: American Society of Health Systems Pharmacists; 2008.

Job ML, Page RL2. Chapter 9: Digoxin. In: Murphy JE, ed. Clinical Pharmacokinetics, 4th edition. Bethesda, MD: American Society of Health Systems Pharmacists; 2008.

Page RL2. Cardiac transplantation. In: Schumock G, Brundage D, Chapman M, et al, eds. Pharmacotherapy Self-Assessment Program, 7th ed. Kansas City, MO: American College of Clinical Pharmacy; January 2007.

Abstracts

Slejko JF, Page RL2, Sullivan P. Cost-effectiveness of statin therapy for chd prevention in adults with elevated c-reactive protein: implications of jupiter. Presented at the Annual Meeting of the Society for Medical Decision Making. Hollywood, CA. October 2009.

Spencer AP, Page RL2. Decreased hospital readmission with nitroprusside in acute decompensated heart failure. Presented at the Heart Failure Society of America Scientific Secessions. Boston, MA. September 2009.

Page RL2, Hogan C, Strongin K, Mills R, Lindenfeld J. Sex and race dictate health care resource utilization by Medicare beneficiaries with heart failure. Presented at the American Heart Association Scientific Sessions. New Orleans, LA; November 2008.

Page RL2, Hogan C, Strongin K, Mills R, Lindenfeld J. Medicare beneficiaries with mild to severe heart failure see 15-23 different providers annually. Presented at the American Heart Association Scientific Sessions. New Orleans, LA; November 2008.

Page RL2, Barton PL, Hogan C, Allen RR, Nair K. Utilization of health care resources by Medicare beneficiaries with heart failure stratified by a three-tier definition. Presented at the AcademyHealth Scientific Meeting. Washington, DC; June 2008.

Page RL2, Strongin K, Mills R, Lindenfeld J. The magnitude of health care resource utilization by Medicare beneficiaries with heart failure. Presented at the American Heart Association Scientific Sessions. Orlando, FL; November 2007.

Wells D, Flynn K, Page RL2, Spencer AP. Effect of amiodarone on argatroban dosing. Presented at the American College of Clinical Pharmacy Spring Meeting. Memphis, TN; April 2007.

Non-Peer Reviewed Publications

Page RL2. Rhythm control in atrial fibrillation: mapping current and emergent therapies. Pharmacy Times. 2009.

Page RL2. Women with hypertension face unique challenges. Pharmacy Times. February 2009.

Page RL2. Women with hypertension: still a battle of the sexes? Pharmacy Times. December 2008.

Page RL2. Reviewing the complexities of morning hypertension. Pharmacy Times. December 2008.

Page RL2. Osteoarthritis: reviewing current standards of care and new therapeutic insights. Pharmacy Times. December 2008.

Page RL2. Women with diabetes and hypertension: a true femme fatale. Pharmacy Times. November 2008.

Page RL2. Morning hypertension and diabetes: a powerful predictor for future complications. Pharmacy Times. November 2008.

Page RL2. Hypertension in pregnancy: an emerging risk for cardiovascular disease. Pharmacy Times. October 2008.

Page RL2. Morning blood pressure and cardiovascular events: a deadly association. Pharmacy Times. October 2008.

Page RL2. Home is where the heart is. New guidelines recommend home blood-pressure monitoring. Pharmacy Times. September 2008.

Page RL2. Preecalmpsia, blood pressure, and maternal outcomes: the potential role for home blood-pressure monitoring. Pharmacy Times. September 2008.

Page RL2. Chronic kidney disease: care across the continuum. Pharmacy Times. April 2008.

Page RL2. Home blood pressure monitoring: a call to action for pharmacists. Pharmacist to pharmacist education. Pharmacy Times. December 2007.

Lewis V, Page RL2. High blood pressure: getting the most out of home monitoring. Pharmacist to patient education. Pharmacy Times. October 2007.

Page RL2. Early to rise: morning surge hypertension and implications for home blood pressure monitoring. Pharmacy Times. June 2007.

Gibson K, Page RL2. What’s UP with morning hypertension. Pharmacist to pharmacist education. Pharmacy Times. April 2007.

Gibson K, Page RL2. Early to rise? Your blood pressure may be too! Pharmacist to patient education. Pharmacy Times. April 2007.

Videotapes

Best in Session: Medicare beneficiaries with mild to severe heart failure see 15-23 different providers annually. American Heart Association Scientific Secessions. New Orleans, LA; November 2008.

2

 Honors and Awards

Public Health Systems Research Interest Group Student Award, AcademyHealth, 2008

Appreciation Award, American Society of Health Systems Pharmacists, 2004

Chancellor’s Teaching Award, UCHSC, 2004

Phi Lamda Sigma, UCHSC School of Pharmacy, Alpha Xi Chapter, 2001

Excellence in Teaching, UCHSC, Pharm.D, Class of 2004, 2001

Excellence in Teaching, UCHSC, Pharm. D, 1999

President’s Teaching Award, UCHSC, 1999

The Ciba-Giegy Netter Second Honor Graduate Award, 1994

The Smith-Kline Beecham Award for Outstanding Patient Care, 1994

The Mylan Pharmaceuticals Award for Excellence in Pharmacy, 1994

Kappa Psi Scholarship Honors Award, 1994

Who’s Who Among American Universities and Colleges, 1993

Rho Chi Honor Society, 1993

MUSC Dean’s List, all semesters, 1991-1996

Alpha Epsilon Delta, the Premedical Honor Society, 1989

3